BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Alesta Therapeutics B.V., a private Dutch company that develops oral small molecule therapies for rare diseases. The total potential deal value is up to $490 million, consisting of an upfront payment and future development-based milestones.
Key Details
- Transaction Terms: The acquisition includes a $275 million upfront cash payment and up to $215 million in potential future payments contingent on achieving various development milestones.
- Acquired Company: Alesta Therapeutics is a private company headquartered in the Netherlands focused on developing novel treatments for underserved rare diseases.
- Expected Closing: The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.